PriceTargets.com logo

NASDAQ:ABCL - AbCellera Biologics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.80
  • Forecasted Upside: 153.40 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$11.76 As of 08/8/2022 01:00 AM ET
▲ +0.44 (3.89%)

This chart shows the closing price for ABCL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AbCellera Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABCL

Analyst Price Target is $29.80
▲ +153.40% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for AbCellera Biologics in the last 3 months. The average price target is $29.80, with a high forecast of $40.00 and a low forecast of $20.00. The average price target represents a 153.40% upside from the last price of $11.76.

This chart shows the closing price for ABCL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in AbCellera Biologics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/16/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/12/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/10/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/11/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/10/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/26/2022Piper SandlerBoost Price TargetOverweight$21.00 ➝ $22.00Low
5/11/2022BMO Capital MarketsReiterated RatingBuy$40.00High
5/11/2022Piper SandlerLower Price Target$28.00 ➝ $21.00High
2/25/2022Credit Suisse GroupBoost Price TargetOutperform$39.00 ➝ $40.00Medium
2/25/2022SVB LeerinkLower Price TargetOutperform$25.00 ➝ $20.00High
2/25/2022Piper SandlerLower Price Target$33.00 ➝ $28.00Low
12/21/2021BenchmarkInitiated CoverageBuy$27.00High
12/19/2021Bloom BurtonReiterated RatingBuyLow
11/18/2021Piper SandlerInitiated CoverageOverweight$33.00Medium
8/15/2021SVB LeerinkReiterated RatingBuyLow
8/13/2021Credit Suisse GroupLower Price TargetOutperform$51.00 ➝ $49.00High
6/28/2021Berenberg BankReiterated RatingBuyMedium
5/14/2021Credit Suisse GroupLower Price TargetOutperform$53.00 ➝ $51.00Low
3/30/2021SVB LeerinkLower Price TargetIn-Line ➝ Outperform$52.00 ➝ $45.00Medium
3/30/2021Stifel NicolausLower Price TargetBuy$59.00 ➝ $55.00Medium
3/30/2021Berenberg BankReiterated RatingBuy$53.00Low
3/24/2021BMO Capital MarketsLower Price TargetOutperform$61.00 ➝ $59.00High
2/8/2021SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $52.00High
1/25/2021BMO Capital MarketsBoost Price Target$48.00 ➝ $61.00Low
1/5/2021Berenberg BankInitiated CoverageBuy$53.00N/A
1/5/2021Credit Suisse GroupInitiated CoverageOutperform$52.00N/A
1/5/2021Stifel NicolausInitiated CoverageBuy$59.00N/A
1/5/2021SVB LeerinkInitiated CoverageOutperform$45.00N/A
1/5/2021BMO Capital MarketsInitiated CoverageOutperform$48.00N/A
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/11/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/10/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/12/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/11/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/10/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2022
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2022

Current Sentiment

  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

AbCellera Biologics logo
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $11.76
Low: $11.05
High: $11.92

50 Day Range

MA: $10.00
Low: $7.54
High: $11.76

52 Week Range

Now: $11.76
Low: $5.42
High: $22.63

Volume

3,005,361 shs

Average Volume

1,584,259 shs

Market Capitalization

$3.35 billion

P/E Ratio

18.38

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of AbCellera Biologics?

The following Wall Street analysts have issued reports on AbCellera Biologics in the last twelve months: Benchmark Co., Bloom Burton, BMO Capital Markets, Credit Suisse Group AG, Piper Sandler, and SVB Leerink LLC.
View the latest analyst ratings for ABCL.

What is the current price target for AbCellera Biologics?

5 Wall Street analysts have set twelve-month price targets for AbCellera Biologics in the last year. Their average twelve-month price target is $29.80, suggesting a possible upside of 153.4%. BMO Capital Markets has the highest price target set, predicting ABCL will reach $40.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $20.00 for AbCellera Biologics in the next year.
View the latest price targets for ABCL.

What is the current consensus analyst rating for AbCellera Biologics?

AbCellera Biologics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABCL will outperform the market and that investors should add to their positions of AbCellera Biologics.
View the latest ratings for ABCL.

What other companies compete with AbCellera Biologics?

Other companies that are similar to AbCellera Biologics include Harmony Biosciences, Corcept Therapeutics, Prestige Consumer Healthcare, Amicus Therapeutics and Global Blood Therapeutics. Learn More about companies similar to AbCellera Biologics.

How do I contact AbCellera Biologics' investor relations team?

The company's listed phone number is 604 559 9905 and its investor relations email address is [email protected] The official website for AbCellera Biologics is www.abcellera.com. Learn More about contacing AbCellera Biologics investor relations.